HAL (France)
open access
Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors#873937
- Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer#831976
- PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer#1172615
- Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer#833591
- Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer#865882
Record · ID 350828
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive